Acceleron Pharma Historical PE Ratio image   This XLRN PE ratio history page last updated 11/8/2021
Acceleron Pharma Historical PE Ratio Chart
Data adjusted for XLRN split history

PeriodPriceGAAPAnnualizedPE
Q3 2021
11/4/2021
173.73-1.16-4.64NA
Q2 2021
8/5/2021
127.38-1.05-4.20NA
Q1 2021
5/6/2021
121.83-1.05-4.20NA
Q4 2020
2/25/2021
135.87-0.95-3.80NA
Q3 2020
11/5/2020
109.49-0.66-2.64NA
Q2 2020
8/6/2020
106.46-0.34-1.36NA
Q1 2020
5/11/2020
105.10-0.95-3.80NA
Q4 2019
2/27/2020
86.57-0.44-1.76NA
Q3 2019
11/6/2019
40.27-0.86-3.44NA
Q2 2019
8/5/2019
41.49-0.34-1.36NA
Q1 2019
5/9/2019
41.51-0.74-2.96NA
Q4 2018
2/27/2019
45.88-0.75-3.00NA
Q3 2018
10/30/2018
48.13-0.63-2.52NA
Q2 2018
8/2/2018
43.65-0.63-2.52NA
Q1 2018
5/8/2018
35.99-0.58-2.32NA
Q4 2017
2/27/2018
43.54-0.62-2.48NA
Q3 2017
11/7/2017
35.23-0.65-2.60NA
Q2 2017
8/3/2017
33.22-0.77-3.08NA
Q1 2017
5/8/2017
27.61-0.66-2.64NA
Q4 2016
3/1/2017
28.69-0.51-2.04NA
Q3 2016
11/3/2016
24.86-0.55-2.20NA
Q2 2016
8/4/2016
33.13-0.59-2.36NA
Q1 2016
5/5/2016
30.190.130.5258.1
Q4 2015
2/25/2016
24.18-0.81-3.24NA
Q3 2015
11/4/2015
34.22-0.36-1.44NA
Q2 2015
8/6/2015
27.74-0.32-1.28NA
Q1 2015
5/7/2015
29.50-0.45-1.80NA
Q4 2014
3/2/2015
39.89-0.55-2.20NA
Q3 2014
11/7/2014
30.19-0.25-1.00NA
Q2 2014
8/12/2014
28.43-0.52-2.08NA
Q1 2014
5/15/2014
31.56-0.30-1.20NA
Q4 2013
2/26/2014
46.90-0.64-2.56NA
Q3 2013
11/6/2013
19.53-5.62-22.48NA
Acceleron Pharma PE History Chart
PeriodPriceGAAPTTMPE
Q3 2021
11/4/2021
173.73-1.16-4.21NA
Q2 2021
8/5/2021
127.38-1.05-3.71NA
Q1 2021
5/6/2021
121.83-1.05-3.00NA
Q4 2020
2/25/2021
135.87-0.95-2.90NA
Q3 2020
11/5/2020
109.49-0.66-2.39NA
Q2 2020
8/6/2020
106.46-0.34-2.59NA
Q1 2020
5/11/2020
105.10-0.95-2.59NA
Q4 2019
2/27/2020
86.57-0.44-2.38NA
Q3 2019
11/6/2019
40.27-0.86-2.69NA
Q2 2019
8/5/2019
41.49-0.34-2.46NA
Q1 2019
5/9/2019
41.51-0.74-2.75NA
Q4 2018
2/27/2019
45.88-0.75-2.59NA
Q3 2018
10/30/2018
48.13-0.63-2.46NA
Q2 2018
8/2/2018
43.65-0.63-2.48NA
Q1 2018
5/8/2018
35.99-0.58-2.62NA
Q4 2017
2/27/2018
43.54-0.62-2.70NA
Q3 2017
11/7/2017
35.23-0.65-2.59NA
Q2 2017
8/3/2017
33.22-0.77-2.49NA
Q1 2017
5/8/2017
27.61-0.66-2.31NA
Q4 2016
3/1/2017
28.69-0.51-1.52NA
Q3 2016
11/3/2016
24.86-0.55-1.82NA
Q2 2016
8/4/2016
33.13-0.59-1.63NA
Q1 2016
5/5/2016
30.190.13-1.36NA
Q4 2015
2/25/2016
24.18-0.81-1.94NA
Q3 2015
11/4/2015
34.22-0.36-1.68NA
Q2 2015
8/6/2015
27.74-0.32-1.57NA
Q1 2015
5/7/2015
29.50-0.45-1.77NA
Q4 2014
3/2/2015
39.89-0.55-1.62NA
Q3 2014
11/7/2014
30.19-0.25-1.71NA
Q2 2014
8/12/2014
28.43-0.52-7.08NA
Q1 2014
5/15/2014
31.56-0.30NANA
Q4 2013
2/26/2014
46.90-0.64NANA
Q3 2013
11/6/2013
19.53-5.62NANA
Quotes delayed 20 minutes

Email EnvelopeFree XLRN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Acceleron Pharma (XLRN) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

XNCR PE Ratio History
XOMA PE Ratio History
XRAY PE Ratio History
YMAB PE Ratio History
YMTX PE Ratio History
YTEN PE Ratio History
ZBH PE Ratio History
ZGNX PE Ratio History
ZIOP PE Ratio History
ZNTL PE Ratio History
How should the XLRN historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Acceleron Pharma. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this XLRN Historical PE Ratio page.

What is the average historical PE for XLRN based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The XLRN historical PE ratio using the annualized quarterly earnings method works out to 58.1.

What is the average historical PE for XLRN based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The XLRN historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the Acceleron Pharma Historical PE Ratio information for Acceleron Pharma' stock. The average XLRN historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 58.1. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average XLRN historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this XLRN historical PE result, against the recent PE: when this page was posted on 11/5/2021, the most recent closing price for XLRN had been 173.38, and the most recent quarterly earnings result, annualized, was 0.52. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent XLRN PE on 11/5/2021 based on annualized quarterly EPS was 333.4. Based on XLRN's history, that recent PE is elevated relative to the historical average, with the recent PE 473.8% higher than the historical average PE across our data set for Acceleron Pharma.

For self directed investors doing their due diligence on XLRN or any other given stock, valuation analysis for XLRN can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Acceleron Pharma PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for XLRN. Thanks for visiting, and the next time you need to research XLRN Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.
 

Acceleron Pharma Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2021, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.